Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Cetuximab Plus Biweekly Capecitabine and Oxaliplatin (C-CO2) in the Treatment of Patients With KRAS Wild Type Metastatic Colorectal Cancer

NCT00444678 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT00444678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00444678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Cetuximab Plus Biweekly Capecitabine and Oxaliplatin (C-CO2) in the Treatment of Patients With KRAS Wild Type Metastatic Colorectal Cancer
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2004
Completion date
June 1, 2015
Enrollment
36 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, neoplasm metastasis